Newamsterdam Pharma Co Nv earnings were -$210.5M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest NAMS earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$43.0M, down 55.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, NAMS reported annual earnings of -$251.7M, with 28% growth. The next NAMS earnings date is Aug 7, 2025.
Newamsterdam Pharma Co Nv Earnings Reports & History FAQ
What were Newamsterdam Pharma Co Nv's earnings last quarter?
Newamsterdam Pharma Co Nv (NASDAQ: NAMS) reported Q1 2025 earnings per share (EPS) of -$0.37, up 67.88% year over year. Total NAMS earnings for the quarter were -$42.96 million. In the same quarter last year, Newamsterdam Pharma Co Nv's earnings per share (EPS) was -$1.15.
When does Newamsterdam Pharma Co Nv report earnings?
The next NAMS earnings call is Invalid Date. Add NAMS to your watchlist to be reminded of Newamsterdam Pharma Co Nv's next earnings date.
Is Newamsterdam Pharma Co Nv profitable or losing money?
As of the last Newamsterdam Pharma Co Nv earnings report, Newamsterdam Pharma Co Nv is currently losing money. Newamsterdam Pharma Co Nv's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$203.65 million, a 18.07% decrease year over year.
What was NAMS's earnings growth in the past year?
As of Newamsterdam Pharma Co Nv's earnings date in Q3 2025, Newamsterdam Pharma Co Nv's earnings has grown year over year. NAMS earnings in the past year totalled -$210.51 million.
What are Newamsterdam Pharma Co Nv's earnings expectations?
The current EPS estimate for Newamsterdam Pharma Co Nv's earnings report in Invalid Date is -$0.44.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.